Victoria Socha

DocwireNews

Several therapeutic combinations of immune-oncology (IO) plus vascular endothelial growth factor (VEGF) regimens have demonstrated positive results in phase 3 trials. However, according to <a href="https://www.mskcc.org/locations/directory/memorial-hospital?utm_source=yext&amp;utm_medium=local&amp;utm_content=gmb">Yasser Ged, MBBS, MRCP</a>, and colleagues, there are few data available on outcomes to subsequent therapy in patients on IO-VEGF combination regimens with disease progression.The researchers conducted a retrospective analysis on patients with advanced clear cell renal cell carcinoma (ccRCC) at the Memorial Sloan Kettering Cancer Center and Cleveland Clinic Cancer Institute. Eligible patients had initiated systemic therapy post IO-VEGF regimens, including combinations with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (IO-TKI) and combinations with anti-VEGF monoclonal antibodies (IO-mAB).The primary objective of the analysis was an evaluation of overall survival post IO-VEGF. Secondary objectives included objective response rate (ORR) and progression-free survival, measured by Response Evaluation in Solid Tumors Criteria, version 1,1. Time from the start of systemic therapy post-IO-VEGF to the event of interest was evaluated using Kaplan-Meier methods and log-rank test.A total of 59 patients were treated following discontinuation of IO-VEGF regimens. Of those 59% (n=35) received&nbsp; IO-mAB and 41% (n=24) received IO-TKI.<a href="https://www.docwirenews.com/latest-nephrology-news/keynote-426-outcomes-in-imdc-subgroups/"> International Metastatic RCC Database Consortium</a> scores at the start at the next line of therapy were favorable in 20% of the patients, intermediate in 60%, and poor in 20%.The next line of therapy included VEGFR-TKI monotherapy in 76% of the cohort (n=45), mammalian target of rapamycin inhibitors in 5% (n=3), and unreported clinical trials in 9% (n=5). Regimens that contained VEGFR-TKI (n=51) included cabozantinib (n=22), axitinib (n=17), lenvatinib/everolimus (n=4), pazopanib (n=4), and others (n=4).Median overall survival was 24.5 months; 12-month overall survival rate was 63%. The ORR was 27% (n=14/51) and median progression-free survival was 6.8 months. In comparison of IO-TKI with IO-mAB, there was no difference in post IO-VEGF overall survival (log rank p=.07).&ldquo;Post combination IO-VEGF treatment, most patients received VEGFR-TKIs. In this setting, VEGFR-TKIs continue to show clinical activity similar to historic experiences of patients post VEGF monotherapy,&rdquo; the researchers said.Source: Ged Y, Gupta R, Duzgol C, et al. Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF). Abstract of a poster presented at the American Society of Clinical Oncology 2019 Annual Meeting, June 3, 2019, Chicago, Illinois.

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Latest News

Systemic Therapy after IO-VEGF

ASCO 2019

Several therapeutic combinations of immune-oncology (IO) plus vascular endothelial growth factor (VEGF) regimens have demonstrated positive results in phase 3 trials. However, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe